Pricing Log in Create free account
Friday 6 November 2026 Export XBIT’s income statement to Excel — free account

XBiotech Inc.

XBIT Healthcare Biotechnology

XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million.

EPS
−266.7%
Free cash flow
+25.3%

Quarter to June 2026, against a year earlier

1.88 0.01 +0.53%
Market cap
$57.0M
P/E
0.0×
Fwd P/E
−3.3×
Dividend yield
—
F-score
3/9
Altman Z
11.69
Beneish M
−4.17
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.71
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — 1 —
Sell — — — — — — — — — — — —
Insider Ownership 36.86%

Capital & Financial Ratios $m

Size
Market Cap 57.01
Revenue ttm 4.01
Net income ttm (45.13)
Free cash flow ttm (40.69)
Net debt Q (109.53)
Valuation
P/E 0.00
Forward P/E (3.25) (negative: loss-making)
Price / sales 14.29 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.45
Financial health
Current ratio Q 33.15 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (153.98)
Growth
Revenue growth Q −93.33% (below 0%: shrinking)
Operating income growth Q +3.00% (above 0%: growing)
EPS, this year —
EPS, next year A —
Revenue, next year A −100.00% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −10.5×, against a ten-year median of −8.2×; over the ten years it ranged from −28.7× in 2023 to 15.6× in 2024.
P/S against its own 10 years 18.37%
10-year low 10-year high
P/B against its own 10 years 4.91%
10-year low 10-year high
EV/FCF against its own 10 years 22.63%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2021–22
−100.0%/yr
  1. 2.10 ’21
  2. 0.00 ’22 −100
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 200 173 126 110
Receivables 1 1 0 0
Inventory — — — —
Other — — — —
202 175 127 111
2023 2024 2025 Q'26
Payables 3 2 2 1
ST’ Debt — 10 — —
Other — — — —
6 15 8 3

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 3.14% (16.64%) (16.42%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY20 Estimate 0.06 Actual 0.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY16 −0.42 −0.51 Miss by 0.09
Q1 FY17 −0.47 −0.32 Beat by 0.15
Q2 FY19 −0.15 −0.16 Miss by 0.01
Q1 FY20 0.06 0.00 Miss by 0.06

EPS $

Mar Jun Sep Dec Year
’26 (0.18) (0.22) — — —
’25 (0.36) (0.06) (0.20) (0.88) (1.49)
’24 (0.33) (0.43) (0.16) (0.34) (1.26)
’23 (0.13) (0.29) (0.24) (0.16) (0.81)
’22 (0.18) (0.38) (0.42) (0.10) (1.08)
’21 (0.09) (0.17) (0.11) (0.21) (0.58)
’20 0.00 (0.24) (0.09) (0.06) (0.36)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’22 1 2 2 0 4
’21 5 5 5 5 18
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (5) — — —
’25 (7) (6) (4) (23) (40)
’24 (7) (11) (6) (7) (31)
’23 (5) (9) (1) (3) (19)
’22 (5) (5) (1) (3) (15)
’21 2 73 (3) (2) 69
’20 (61) (12) 7 0 (65)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (5) — — —
’25 (7) (6) (4) (23) (40)
’24 (7) (12) (6) (7) (32)
’23 (5) (9) (2) (4) (19)
’22 (5) (5) (1) (3) (15)
’21 1 71 (4) (2) 66
’20 (61) (12) 7 (3) (69)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — 44 18 4 — — — 4 (69.8%) — — — —
Gross margin, % 0.00 0.00 0.00 0.00 21.48 68.36 83.77 — — — 0.00 +83.8 pt
EBT (53) (33) (21) 718 (13) (25) (34) (24) (39) (45) (45) (1.7%)
EBT margin, % 0.00 0.00 0.00 0.00 (29.15) (138.40) (837.61) 0.00 0.00 0.00 0.00 0.0 pt
Net income (53) (33) (21) 669 (11) (17) (33) (25) (39) (46) (45) (1.6%)
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 1.43 0.61 0.13 0.00 0.00 0.00 0.00 n/m
Earnings (1.63) (0.95) (0.59) 17.17 (0.36) (0.58) (1.08) (0.81) (1.26) (1.49) (1.48) (1.0%)
Cash flow (1.42) (0.96) (0.46) (0.47) (2.11) 2.31 (0.49) (0.62) (1.02) (1.31) (1.33) (0.9%)
Capex (0.43) (0.04) 0.00 (0.01) (0.12) (0.12) (0.02) (0.01) (0.04) (0.01) 0.00 (34.5%)
Free cash flow (1.85) (1.01) (0.47) (0.47) (2.23) 2.19 (0.51) (0.63) (1.06) (1.32) (1.33) (3.7%)
Book value 1.82 1.73 1.16 19.40 11.31 8.97 7.90 7.19 5.98 4.60 4.21 +10.8%
Shares, m 32 35 36 39 31 30 30 30 30 30 30 (0.7%)
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 0.00 — — — 0.00 0.0
P/S — — — — 10.96 18.18 25.66 — — — 14.29 18.3
P/B — — — — 1.38 1.24 0.43 — — — 0.45 1.0
EV/Sales — — — — 5.57 5.30 (28.58) — — — (10.46) (5.9)
EV/FCF — — — — (3.56) 1.48 7.44 — — — 1.02 1.8
Cash, $m
Cash, $m Operating cash flow (46) (34) (17) (18) (65) 69 (15) (19) (31) (40) (41) (1.6%)
Capex (14) (1) 0 0 (4) (4) (1) 0 (1) 0 0 (35.0%)
Free cash flow (60) (35) (17) (18) (69) 66 (15) (19) (32) (40) (41) (4.3%)
Balance, $m
Balance, $m Working capital 29 31 14 656 322 243 216 196 159 119 108 +17.0%
Net debt (34) (32) (16) (715) (237) (237) (217) (200) (162) (126) (110) +15.5%
Shareholders’ equity 59 60 41 756 349 269 240 219 182 140 128 +10.1%
Returns, %
Returns, % ROA (59.82) (50.99) (39.39) 155.27 (1.92) (5.54) (12.62) (10.39) (18.10) (26.08) (28.90) +33.7 pt
ROIC (133.29) (74.97) (51.30) (47.57) (10.27) (48.38) (94.03) (124.55) (133.79) (235.17) (159.18) (101.9) pt
ROE (65.09) (55.61) (41.63) 167.78 (2.03) (5.64) (12.91) (10.69) (19.21) (28.23) (29.94) +36.9 pt
People
People Employees 106 51 56 49 91 97 85 82 92 85 — (2.4%)
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.48 0.19 0.05 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

XBiotech Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SPRO Spero Therapeutics, Inc. $59.4M 7.4× — (loss-making) −95.61% (below 0%: shrinking) n/m +69.73% (above 0%: growing) 100.00% 0.00% Compare
CRDF Cardiff Oncology, Inc. $58.8M — (loss-making) — (loss-making) −14.05% (below 0%: shrinking) n/m −41.36% (below 0%: shrinking) 100.00% (9,245.19%) Compare
GOSS Gossamer Bio, Inc. $57.6M — (loss-making) — (loss-making) −19.59% (below 0%: shrinking) n/m +16.32% (above 0%: growing) 100.00% (282.25%) Compare
TELO Telomir Pharmaceuticals, Inc. $57.5M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
XBIT XBiotech Inc. $57.0M — (loss-making) — (loss-making) −93.33% (below 0%: shrinking) n/m +25.25% (above 0%: growing) 0.00% 0.00%
CLNN Clene Inc. $56.4M — (loss-making) — (loss-making) +273.33% (above 0%: growing) n/m −16.61% (below 0%: shrinking) 71.43% (11,333.93%) Compare
XLO Xilio Therapeutics, Inc. $55.9M — (loss-making) — (loss-making) +131.22% (above 0%: growing) n/m −26.23% (below 0%: shrinking) 100.00% (18.68%) Compare
CRBP Corbus Pharmaceuticals Holdings, Inc. $55.3M — (loss-making) — (loss-making) −92.09% (below 0%: shrinking) n/m −78.52% (below 0%: shrinking) 0.00% 0.00% Compare
BOLD Boundless Bio, Inc. $54.8M — (loss-making) — — n/m −76.90% (below 0%: shrinking) — 0.00% Compare
Median of peers $57.0M — — −16.82% — −33.79% 100.00% (9.34%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 2 October 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 30.10m 27.10m (41.56)
2024 6.25m 6.25m 2.25
2023 5.56m 5.56m 13.96
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

XBiotech Inc. (XBIT) Latest News

23 Oct

Impact 4 · · GlobeNewswire

19 Oct

Impact 4 · · GlobeNewswire

15 Jun

Impact 4 ·

13 Mar

Impact 4 · · Associated Press Finance

19 Dec

Impact 3 · · Simply Wall St.

12 Nov

Impact 4 · · Simply Wall St.
Impact 3 ·

28 Aug

Impact 3 · · Simply Wall St.

13 Aug

Impact 3 · · Associated Press Finance

2 Jul

Impact 3 · · Simply Wall St.

16 May

Impact 3 · · Simply Wall St.

23 Dec

Impact 4 · · GlobeNewswire

12 Aug

Impact 3 · · Associated Press Finance

18 Jun

Impact 4 · · GlobeNewswire

8 Mar

Impact 3 · · Zacks

7 Mar

Impact 3 · · Zacks

25 Feb

Impact 3 · · Simply Wall St.

4 Jan

Impact 4 · · GlobeNewswire

5 Dec

Impact 3 · · Simply Wall St.

14 Nov

Impact 4 · · GlobeNewswire

26 Sep

Impact 4 · · GlobeNewswire

16 Sep

Impact 3 · · Simply Wall St.

30 Aug

Impact 4 · · GlobeNewswire

8 Aug

Impact 4 · · GlobeNewswire

25 Jul

Impact 4 · · Simply Wall St.

22 May

Impact 4 · · GlobeNewswire

17 May

Impact 4 · · GlobeNewswire
stockrow.com/XBIT · Data as of Dec 31, 2022 · For information only; not investment advice. · © 2026 stockrow.com